96 related articles for article (PubMed ID: 8128920)
1. [Effect of lentinan for advanced prostate carcinoma].
Tari K; Satake I; Nakagomi K; Ozawa K; Oowada F; Higashi Y; Negishi T; Yamada T; Saito H; Yoshida K
Hinyokika Kiyo; 1994 Feb; 40(2):119-23. PubMed ID: 8128920
[TBL] [Abstract][Full Text] [Related]
2. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K
Hepatogastroenterology; 1999; 46(28):2662-8. PubMed ID: 10522061
[TBL] [Abstract][Full Text] [Related]
3. [TS-1/CDDP/Lentinan combination chemotherapy for inoperable advanced gastric cancer].
Nagahashi S; Suzuki H; Nishiwaki M; Okuda K; Kurosawa Y; Terada S; Sugihara T; Andou K; Hibi T
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1999-2003. PubMed ID: 15570928
[TBL] [Abstract][Full Text] [Related]
4. [Results of phase III study of lentinan].
Taguchi T; Furue H; Kimura T; Kondo T; Hattori T; Itoh I; Ogawa N
Gan To Kagaku Ryoho; 1985 Feb; 12(2):366-78. PubMed ID: 3918510
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.
Isoda N; Eguchi Y; Nukaya H; Hosho K; Suga Y; Suga T; Nakazawa S; Sugano K
Hepatogastroenterology; 2009; 56(90):437-41. PubMed ID: 19579616
[TBL] [Abstract][Full Text] [Related]
6. [Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):387-93. PubMed ID: 6349538
[TBL] [Abstract][Full Text] [Related]
7. [A comparative clinical trial with tegafur plus lentinan treatment at two different doses in advanced cancer].
Wada T; Nishide T; Hatayama K; Chang SW; Tatsuta M; Yasutomi M
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2509-12. PubMed ID: 3113339
[TBL] [Abstract][Full Text] [Related]
8. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
[TBL] [Abstract][Full Text] [Related]
9. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
Nimura H; Mitsumori N; Tsukagoshi S; Nakajima M; Atomi Y; Suzuki S; Kusano M; Yoshiyuki T; Tokunaga A
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1289-96. PubMed ID: 14518408
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey.
Taguchi T
Cancer Detect Prev Suppl; 1987; 1():333-49. PubMed ID: 3121179
[TBL] [Abstract][Full Text] [Related]
11. [Ifosfamide in combined hormonochemotherapy on prostate cancer].
Fujita K; Matsushima H; Nakano M; Kaneko T
Gan To Kagaku Ryoho; 1994 Feb; 21(2):227-30. PubMed ID: 8311493
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
Shimizu K; Watanabe S; Watanabe S; Matsuda K; Suga T; Nakazawa S; Shiratori K
Hepatogastroenterology; 2009; 56(89):240-4. PubMed ID: 19453066
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
15. [A case of hepatocellular carcinoma in an elderly patient that improved upon combination therapy of Lentinan and Tegafur].
Takahashi T; Hori Y; Isogawa S; Saho M; Yoshida H; Yokoyama K; Watanabe M; Nakagawa S
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1517-9. PubMed ID: 1697155
[TBL] [Abstract][Full Text] [Related]
16. [Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer].
Tanabe H; Imai N; Takechi K
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1657-67. PubMed ID: 2230448
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
18. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
19. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
Amato RJ; Teh BS; Henary H; Khan M; Saxena S
Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
